News & Updates
Filter by Specialty:
Baricitinib may improve hair regrowth in alopecia areata
A once-daily dose of oral baricitinib may encourage hair regrowth in patients with severe alopecia areata, according to results of the phase III BRAVE-AA studies presented at AAD 2022.
Baricitinib may improve hair regrowth in alopecia areata
02 May 2022
New oral tyrosine kinase 2 inhibitor shows promise against moderate-to-severe plaque psoriasis
PF-06826647, a novel tyrosine kinase 2 inhibitor in development, outperforms placebo at reducing disease severity in patient with moderate-to-severe plaque psoriasis, reveals a new trial.
New oral tyrosine kinase 2 inhibitor shows promise against moderate-to-severe plaque psoriasis
23 Apr 2022
Ritlecitinib, brepocitinib show promise against scalp alopecia areata
Ritlecitinib and brepocitinib lead to improvements in scalp alopecia areata and its associated biomarkers, reveals a recent substudy of a phase 2a trial.
Ritlecitinib, brepocitinib show promise against scalp alopecia areata
22 Apr 2022
Topical therapy plus microneedling safe, effective in melasma management
Use of microneedling appears to be a beneficial adjunct to topical medications in the treatment of melasma, suggests a recent study.
Topical therapy plus microneedling safe, effective in melasma management
03 Apr 2022
Abrocitinib effectively manages AD flares
Rescue therapy using the Janus kinase 1 inhibitor abrocitinib combined with topical medicated therapy recaptured efficacy responses and had a favourable safety profile in individuals with moderate-to-severe atopic dermatitis (AD) who experienced flare during the maintenance period of the phase III randomized-withdrawal JADE REGIMEN trial.